<DOC>
	<DOCNO>NCT02836470</DOCNO>
	<brief_summary>The purpose study establish preliminary evidence efficacy , safety , tolerability LB1148 treatment post-operative ileus intra-abdominal adhesion subject undergo elective bowel resection .</brief_summary>
	<brief_title>A Study Evaluate LB1148 Return Gastrointestinal Function Adhesions Subjects Undergoing Bowel Resection</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , parallel , placebo-controlled , proof-of-concept , adaptive design , Phase 2 study evaluate LB1148 return gastrointestinal function reduction post-operative ileus intra-abdominal adhesion subject undergo elective bowel resection surgery without plan stoma .</detailed_description>
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Ileus</mesh_term>
	<criteria>Scheduled undergo elective ( nonemergent ) bowel resection without plan stoma via laparotomy minimally invasive technique . This include subject resection small intestine , colon , rectum perform elect indication . Has inform nature study ( either subject legal representative ) , agree provision , provide write informed consent . Subjects eligible participation study meet ANY follow exclusion criterion : &lt; 18 &gt; 80 year age . Requires emergency bowel surgery . Has 1 abdominal surgery , exclude current , inflammatory bowel disease , include , limited , inflammatory bowel disease ( IBD ) , Crohn 's Disease , ulcerative colitis . Note : This apply previous surgery hernia repair unrelated IBD . American Society Anesthesiologists ( ASA ) Class 4 5 . Insulin dependent diabetes mellitus . Known inability take study drug orally ( i.e . complete small bowel obstruction ) . Has contraindication potential risk factor take TXA . These include subject : 1 . Known sensitivity TXA ; 2 . Recent craniotomy ( past 30 day ) ; 3 . Active cerebrovascular bleed ; 4 . Active thromboembolic disease ( deep vein thrombosis , pulmonary embolism , cerebral thrombosis , ischemic stroke , acute coronary syndrome ) ; 5 . Acute promyelocytic leukemia take alltrans retinoic acid remission induction , 6 . Continuing use combine hormonal contraceptive combine hormonal replacement therapy ( include combine hormonal pill , patch , vaginal ring ) . Has follow risk factor thromboembolic disease : 1 . Known medical history congenital acquire thrombophilia , limited patient : Sickle cell disease ; Nephrotic syndrome ; Factor V Leiden ; Prothrombin gene mutation ; Protein C S deficiency ; Antithrombin III deficiency ; Antiphospholipid syndrome . 2 . Stage IV malignant neoplasm ; 3 . Neurologic paresis , partial paralysis , paralysis ; 4 . Pacemaker ; 5 . History pulmonary embolism , deep vein thrombosis , cerebrovascular accident , rental venous/arterial occlusion ; History current seizure disorder . Patients myeloproliferative disorder . Body Mass Index ( BMI ) &gt; 40 . Any condition , opinion Investigator , would preclude subject appropriate candidate study , include severe renal hepatic impairment . Planned treatment alvimopan ( EnteregÂ® ) study participation period . Received investigational therapy within 4 week prior Randomization Chronic opioid usage , define American Pain Society daily neardaily use opioids least 90 day . Female subject childbearing potential positive urine serum pregnancy test taking ( willing take ) acceptable birth control measure ( abstinence , intrauterine device , contraceptive implant barrier method ) Day 30 . Additionally , woman lactate insist breast feeding within 5 day last dose study drug . Known history radiation enteritis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Post-operative Ileus</keyword>
	<keyword>Post-Operative Abdominal Adhesions</keyword>
	<keyword>Return Gastrointestinal Function</keyword>
	<keyword>Anastomosis</keyword>
	<keyword>Enterotomy</keyword>
	<keyword>Enterostomy</keyword>
	<keyword>Colorectal Surgery</keyword>
	<keyword>Intestines Surgery</keyword>
</DOC>